VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
TRDA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
TRDAEntrada Therapeutics, Inc.
$5.03$195M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
TRDA logo

Entrada Therapeutics, Inc.

TRDA
NASDAQ · Cell & Gene Therapy
$5.03
At close - Nov 18, 4:00 PM EST - USD
Market Cap$195M
P/E-1.3x
52W High$16.45
Volume815.22K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Cash Runway Shrinks Amid Revenue Collapse

Entrada's quarterly revenue fell from $94.7M in 2024Q2 to $898.0K in 2026Q2 (down 53.9% year over year), while R&D of $35.4M and SG&A of $10.5M drive operating losses near $45.0M per quarter, suggesting the fundamental story now rests almost entirely on pipeline progress rather than commercial traction.

GrowthContracting
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

TRDA price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

9/12 Beats

EPS beat 9 of last 12 quarters

02

Valuation risk

-105% Peers

P/E is 105% below peer median

03

Market leadership

RS 24 · Lag

Laggard (Underperforming 76% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 5

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
TRDA-49.95%
S&P 500 (^GSPC)+6.88%
1-Year Return
TRDA-42.97%
S&P 500 (^GSPC)+10.62%
3-Year Return
TRDA-69.16%
S&P 500 (^GSPC)+61.53%
5-Year Return
TRDA-85.13%
S&P 500 (^GSPC)+60.15%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y Low
-1.3x
Forward P/E
N/A
EV/EBITDA
N/A
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-1.3x
10.3x
0th· Low
EV/EBITDA
N/A
12.5x
N/A
Price/FCF
N/A
3.7x
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
No DCF Model AvailableIntrinsic value modeling is not supported for this equity.

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$25M-87.9% YoY
Net income FY25
-$144M-319.0% YoY
Free cash flow FY25
-$130M-189.7% YoY
Operating margin FY25
-613.7%-636.0 pts YoY
ROIC (FY25)-35.8%
Avg ROIC 5Y-24.6%
ROE (TTM)-64%
Piotroski Score2 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate9/12 (75%)
Revenue Beat Rate6/12 (50%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 5, 2026
-$0.94+6.9%
vs -$1.01
$905,000-60.6%
vs $2M
Q3 2026
Aug 5, 2026
-$1.01+3.7%
vs -$1.05
$898,000-59.8%
vs $2M
Q2 2026
May 7, 2026
-$0.95+10.4%
vs -$1.06
$875,000-70.0%
vs $3M
Q1 2026
Feb 26, 2026
-$0.94+28.8%
vs -$1.32
$1M-82.5%
vs $7M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Zacks Investment Research·Nov 5, 2026
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates

Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to a loss of $1.06 per share a year ago.

GlobeNewsWire·Nov 5, 2026
Entrada Therapeutics Reports Third Quarter 2026 Financial Results

-- All ELEVATE-44-201 Cohort 1 participants have completed open-label dosing, with data expected to be received by year-end 2026 -- -- Company on track to report ELEVATE-44-201 Cohort 2 data in Q1 2027 – -- ELEVATE-45-201 Cohort 1 data reported in October 2026 met the primary objective of favorable safety and tolerability at an initial dose of 5 mg/kg -- -- ELEVATE-45-201 Cohort 2 enrollment complete and Company on track to report data in H1 2027 -- -- Expected cash runway extended into Q4 2027 with $193 million in cash, cash equivalents and marketable securities as of September 30, 2026 -- BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported financial results for the third quarter ended September 30, 2026, and highlighted recent business updates. “The October Cohort 1 data from ELEVATE-45-201 marked our third consecutive readout demonstrating encouraging safety and tolerability across our clinical programs,” said Dipal Doshi, Chief Executive Officer of Entrada Therapeutics.

Defense World·Oct 22, 2026
Head to Head Review: Entrada Therapeutics (NASDAQ:TRDA) versus X4 Pharmaceuticals (NASDAQ:XFOR)

Entrada Therapeutics (NASDAQ: TRDA - Get Free Report) and X4 Pharmaceuticals (NASDAQ: XFOR - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, earnings and profitability. Insider and Institutional Ownership 86.4% of Entrada

GlobeNewsWire·Oct 21, 2026
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer

BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Linea Aspesi as Chief People Officer. “Linea has a proven track record of scaling organizations and developing high-performing teams from discovery through commercial stages,” said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics.

Filtered for Entrada Therapeutics, Inc.More Headlines
04

Compare before deciding

Benchmark TRDA against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Entrada Therapeutics, Inc. (TRDA)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
TRDA logoTRDAEntrada Therapeutics, Inc.Current
$5.03$195.27M-1.32-87.94%-4057.98%-64%—
ARWR logoARWRArrowhead Pharmaceuticals, Inc.
$43.11$6.07B-8.43-45.65%-160.64%-172.62%—
NTLA logoNTLAIntellia Therapeutics, Inc.
$9.77$1.1B-3.2116.92%-805.75%-64.73%—
BEAM logoBEAMBeam Therapeutics Inc.
$21.01$2.16B-20.54120.01%-73.04%-9.69%—
EDIT logoEDITEditas Medicine, Inc.
$1.77$271.63M-3.7625.39%-144.95%-130.43%—
CRSP logoCRSPCRISPR Therapeutics AG
$40.19$3.88B-8.52-89.97%-1812.07%-25.59%—

Compare TRDA vs Peers

Entrada Therapeutics, Inc. (TRDA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ARWR

Most directly comparable listed peer for TRDA.

Scale Benchmark

vs LLY

Larger-name benchmark to compare TRDA against a more recognizable public peer.

Peer Set

Compare Top 5

vs ARWR, NTLA, BEAM, EDIT

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

TRDA SEC Filings & Documents

Entrada Therapeutics, Inc. (TRDA) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 5, 2026·SEC

Material company update

Jun 10, 2026·SEC

Material company update

May 19, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 26, 2026·SEC

FY 2025

Feb 27, 2025·SEC

FY 2024

Mar 13, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 5, 2026·SEC

FY 2026

May 7, 2026·SEC

FY 2025

Nov 6, 2025·SEC

Get notified when TRDA posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

TRDA Frequently Asked Questions

Entrada Therapeutics, Inc. (TRDA) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Entrada Therapeutics, Inc.'s revenue?

Entrada Therapeutics, Inc. (TRDA) reported $4.0M in revenue over the trailing twelve months. Revenue was $25.4M in fiscal year 2025.

How fast is Entrada Therapeutics, Inc. growing?

Entrada Therapeutics, Inc. (TRDA) revenue fell by 93.5% over the trailing twelve months, compared with the twelve months before.

Is TRDA profitable?

No. Entrada Therapeutics, Inc. (TRDA) reported a net loss of $161.4M over the trailing twelve months.

Dividend & Returns
What is TRDA's return on equity?

Entrada Therapeutics, Inc. (TRDA) had a return on equity (ROE) of -64.0% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Entrada Therapeutics, Inc.'s free cash flow?

Entrada Therapeutics, Inc. (TRDA) had negative free cash flow of $136.3M over the trailing twelve months.

What if you invested $1,000 in TRDA back in 2019?

Total return calculator · dividends reinvested · 7+ years of data

See returns →